英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
druplo查看　druplo　在百度字典中的解释百度英翻中〔查看〕
druplo查看　druplo　在Google字典中的解释Google英翻中〔查看〕
druplo查看　druplo　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Targeting ALK Rearrangements in NSCLC: Current State of the Art
    Currently, six ALK-target agents have been approved to treat advanced ALK+ NSCLC, including crizotinib, alectinib, ceritinib, ensartinib, brigatinib, and lorlatinib These targeted agents induce durable responses and improve survival outcomes Treatment with ALK inhibitors is recognized as the standard of care for advanced ALK+ NSCLC
  • Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer
    Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
  • A comprehensive evaluation of ALK inhibitors in the first-line . . .
    ALK inhibitors constitute the first-line therapy for patients afflicted with ALK-positive advanced NSCLC At present, six ALK inhibitors have obtained regulatory approval in China for this specific indication and have been endorsed by the NCCN, ESMO, and CSCO guidelines, with recommendations largely grounded in their efficacy and safety profiles
  • Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non . . .
    These results coupled with prolonged intracranial efficacy and absence of new safety signals represent an unprecedented outcome for patients with advanced ALK -positive NSCLC and set a new benchmark for targeted therapies in cancer
  • FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC
    The FDA has approved ensartinib for patients with ALK+ locally advanced or metastatic NSCLC who have not previously received an ALK inhibitor
  • ALK inhibitors in non-small cell lung cancer: the latest evidence and . . .
    The treatment of patients with advanced non-small cell lung cancer (NSCLC) harbouring chromosomal rearrangements of ALK (anaplastic lymphoma kinase) was revolutionized by crizotinib, a small molecule inhibitor of ALK, ROS1 and MET Unfortunately,
  • Evaluating Diagnostic and Treatment Timelines for ALK-Positive NSCLC . . .
    MicroabstractThe ALK Life Study analyzed diagnostic and treatment timelines in 1288 ALK-positive NSCLC patients from 71 countries The median time to diagnosis was 45 days, and time to TKI treatment was 30 days for advanced-stage patients Younger age, comorbidities, and geographic factors were linked to delays Outcomes may be improved by raising awareness amongst clinicians of the frequency
  • Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A Marathon . . .
    Rearrangements involving the anaplastic lymphocyte kinase (ALK) gene are found in 3% to 7% of NSCLC 1 Multiple ALK inhibitors, including first generation (crizotinib), second-generation (ceritinib, alectinib, brigatinib, and ensartinib), and third-generation (lorlatinib) ALK inhibitors have exhibited robust efficacy in patients with advanced ALK-rearranged NSCLC 1 In this issue of the Journal
  • Triana Biomedicines - Press Release 3 25 26
    The Phase 1 portion will consist of a dose escalation design, enrolling ALK+ NSCLC patients, who have been previously treated with standard of care ALK tyrosine kinase therapies The Phase 2 portion will further evaluate and characterize the efficacy and safety of TRI-611 across different patient cohorts
  • Sustained Complete Response to Brigatinib in a Young ALK+ NSCLC Patient
    Managing Resistance in ALK-Positive Lung Cancer - Case Applying Precision Oncology Approach In this expert case presentation, Dr Akhil Kapoor shares the journey of a young, non-smoking patient with ALK-positive non-small cell lung cancer who developed resistance to alectinib due to an ALK I1171N mutation Through repeat molecular testing, the treatment was precisely adapted to brigatinib





中文字典-英文字典  2005-2009